Pharmacological Targeting of DHHC9 ‐Mediated STRN4 Palmitoylation to Suppress YAP ‐Driven Cancer Metastasis
Journal of Cellular and Molecular Medicine · 2025
DOI: 10.1111/jcmm.70815 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Yang Tian und 24 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China. Hauptthemen laut MEDLINE: Lipoylation, Acyltransferases, Adaptor Proteins, Signal Transducing, Transcription Factors. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Basic Science Research Project for Higher Education Institutions in Jiangsu Province, Xuzhou Medical University Undergraduate Training Program for Innovation and Entrepreneurship & Student Research Training Program, Young Scientists Fund of the National Natural Science Foundation of Jiangsu.
Abstract (Originalsprache)
Protein S‐palmitoylation, a dynamic and reversible post‐translational modification involving the attachment of palmitate to cysteine residues, is a key regulator of protein functionality and cellular signalling. Dysregulation of this modification has emerged as a critical driver of cancer progression. Among the 23 DHHC palmitoyl transferases responsible for catalysing S‐palmitoylation, aberrant expression of specific members is linked to tumorigenesis and development, underscoring their potential as promising therapeutic targets. However, the cancer‐specific roles and substrates of individual DHHC enzymes remain poorly characterised. In this study, we identified DHHC9 as a crucial regulator of adenocarcinoma progression, including colorectal and lung cancers. Functional studies demonstrated that DHHC9 knockdown profoundly inhibited cell migration in vitro and tumour metastasis in vivo. Proteomic and functional analyses revealed that STRN4, a core component of the STRIPAK complex, was palmitoylated by DHHC9 at cysteine 701. The STRN4 palmitoylation reduced YAP phosphorylation, promoted nuclear translocation of YAP and activated downstream Hippo pathway transcriptional targets—including CCN1, CCN2 and ANKRD1—thereby driving cancer cell migration. Notably, we discovered two small molecules, Treprostinil and 10‐HCPT, as potent DHHC9 inhibitors that effectively suppressed adenocarcinoma cell migration. Our findings define the DHHC9‐STRN4‐YAP axis as a novel mechanism linking palmitoylation to phosphatase regulation and Hippo pathway dysregulation, unveiling DHHC9 as a highly promising therapeutic target in cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.
- Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
- State Key Laboratory Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.
- National Demonstration Center for Experimental Basic Medical Education, Xuzhou Medical University, Xuzhou, Jiangsu, China.
- Jiangsu Province Key Laboratory of Immunity and Metabolism, Xuzhou Medical University, Xuzhou, Jiangsu, China.
- Department of Pathogenic Biology and Immunology, Xuzhou Medical University, Xuzhou, Jiangsu, China.
ORCID-Profile: Junnian Zheng, Yang Sun
Förderung
- Basic Science Research Project for Higher Education Institutions in Jiangsu Province
- Xuzhou Medical University Undergraduate Training Program for Innovation and Entrepreneurship & Student Research Training Program
- Young Scientists Fund of the National Natural Science Foundation of Jiangsu
- Postgraduate Research &Practice Innovation Program of Jiangsu Province
- National Natural Science Foundation of China
- National Demonstration Center for Experimental Basic Medical Science Education (Xuzhou Medical University) Student Science and Technology Innovation
- Xuzhou Medical University
Zitieren
APA
Tian, Y., Li, W., Zhai, Q., Yu, Y., Yuan, J., Ma, Y., Yang, J., Li, M., Chang, W., Li, W., Huang, K., Sun, C., Zeng, C., Sun, Y., Gu, J., Zhang, H., Li, D., Yu, Y., Hu, L., …, & Sun, Y. (2025). Pharmacological Targeting of DHHC9 ‐Mediated STRN4 Palmitoylation to Suppress YAP ‐Driven Cancer Metastasis. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70815
Vancouver
Tian Y, Li W, Zhai Q, Yu Y, Yuan J, Ma Y, et al. Pharmacological Targeting of DHHC9 ‐Mediated STRN4 Palmitoylation to Suppress YAP ‐Driven Cancer Metastasis. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70815
BibTeX
@article{Tian2025,
author = {Tian, Yang and Li, Wei and Zhai, Qing and Yu, Ying and Yuan, Jiaxin and Ma, Yan and Yang, Jingjing and Li, Mingyue and Chang, Wenwen and Li, Wenjing and Huang, Keke and Sun, Chongran and Zeng, Chen and Sun, Yingdi and Gu, Jiabao and Zhang, Huilin and Li, Dameng and Yu, Yanan and Hu, Lu and Zhang, Peng and Ma, Bo and Zheng, Junnian and Li, Pan and Guo, Feng and Sun, Yang},
title = {Pharmacological Targeting of DHHC9 ‐Mediated STRN4 Palmitoylation to Suppress YAP ‐Driven Cancer Metastasis},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
doi = {10.1111/jcmm.70815}
}
EUVIMED